Stonegate Capital Partners has updated its coverage on NU Skin Enterprises Inc. (NYSE: NUS), reporting fourth quarter 2025 financial results that aligned with the low end of revenue guidance and the high end of EPS guidance. For the quarter, NUS reported revenue of $370.3 million, adjusted net income of $14.5 million, and adjusted EPS of $0.29. This compares to Stonegate's estimates of $380.2 million, $15.1 million, and $0.30, respectively.
The company's Rhyz segment contributed $48.52 million in revenue, with $42.45 million from Manufacturing and $6.07 million from Rhyz Other. The Nu Skin core business achieved a 77.6% gross margin and benefited from disciplined cost management, as selling expenses declined to 40.8% of core business revenue. Management highlighted strategic penetration into India and other emerging markets, along with margin expansion and a one-time tax benefit, as key drivers for fiscal year 2025 results.
Key takeaways from the announcement include the advancing rollout of Prism iO in the first half of 2026, with India pre-launch underway and full market opening expected in the second half of 2026. The company provided FY26 EPS guidance with a midpoint of $1.00. Despite weaker-than-expected top-line performance, management remains focused on executing strategic initiatives to drive growth.
For more details, view the full announcement here. Stonegate Capital Partners, through its affiliate Stonegate Capital Markets (member FINRA), offers investor relations, equity research, and investment banking services for public companies.
